|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910298445503321 |
|
|
Titolo |
Advances in Cancer Biomarkers : From biochemistry to clinic for a critical revision / / edited by Roberto Scatena |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2015 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2015.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (361 p.) |
|
|
|
|
|
|
Collana |
|
Advances in Experimental Medicine and Biology, , 0065-2598 ; ; 867 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer - Research |
Oncology |
Pharmacology |
Cancer Research |
Pharmacology/Toxicology |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
Prelims -- I Generality.- II Tumor markers-a critical revision -- Enzymes.- Hormones -- Oncofetal proteins.- Cytokeratins -- Carbohydrate markers -- Blood group antigens.- Genetic markers -- Various protein markers -- III Perspectives.- The role of Circulating tumor Cells as tumor markers -- Index. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by |
|
|
|
|